These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 18382085)

  • 1. Cytapheresis in inflammatory bowel diseases: current evidence and perspectives.
    Danese S; Angelucci E; Stefanelli T; Omodei P; Luigiano C; Finazzi S; Pagano N; Repici A; Vecchi M; Malesci A
    Digestion; 2008; 77(2):96-107. PubMed ID: 18382085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective leukocyte apheresis for the treatment of inflammatory bowel disease.
    Abreu MT; Plevy S; Sands BE; Weinstein R
    J Clin Gastroenterol; 2007; 41(10):874-88. PubMed ID: 18090155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study.
    Sakata Y; Iwakiri R; Amemori S; Yamaguchi K; Fujise T; Otani H; Shimoda R; Tsunada S; Sakata H; Ikeda Y; Ando T; Nakafusa Y; Fujimoto K
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):629-33. PubMed ID: 18679064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy?
    Saniabadi AR; Hanai H; Suzuki Y; Ohmori T; Sawada K; Yoshimura N; Saito Y; Takeda Y; Umemura K; Kondo K; Ikeda Y; Fukunaga K; Nakashima M; Beretta A; Bjarnason I; Lofberg R
    J Clin Apher; 2005 Oct; 20(3):171-84. PubMed ID: 15892107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukocytapheresis in the treatment of inflammatory bowel disease: Current position and perspectives.
    Vernia P; D'Ovidio V; Meo D
    Transfus Apher Sci; 2010 Oct; 43(2):227-9. PubMed ID: 20817610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease.
    Hibi T; Inoue N; Ogata H; Naganuma M
    J Gastroenterol; 2003 Mar; 38 Suppl 15():36-42. PubMed ID: 12698869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease.
    Hanai H; Iida T; Takeuchi K; Watanabe F; Yamada M; Kikuyama M; Maruyama Y; Iwaoka Y; Hirayama K; Nagata S; Takai K
    Am J Gastroenterol; 2008 May; 103(5):1210-6. PubMed ID: 18177452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytapheresis (CAP) with leukocyte removal filter/bead column as one therapeutic option for inflammatory bowel disease.
    Sawada K
    Transfus Apher Sci; 2017 Oct; 56(5):689-697. PubMed ID: 28986009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus.
    Bourreille A; Ignjatovic A; Aabakken L; Loftus EV; Eliakim R; Pennazio M; Bouhnik Y; Seidman E; Keuchel M; Albert JG; Ardizzone S; Bar-Meir S; Bisschops R; Despott EJ; Fortun PF; Heuschkel R; Kammermeier J; Leighton JA; Mantzaris GJ; Moussata D; Lo S; Paulsen V; Panés J; Radford-Smith G; Reinisch W; Rondonotti E; Sanders DS; Swoger JM; Yamamoto H; Travis S; Colombel JF; Van Gossum A;
    Endoscopy; 2009 Jul; 41(7):618-37. PubMed ID: 19588292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent understanding of leukocytapheresis (LCAP) for the treatment of inflammatory bowel disease.
    Mitsuyama K; Yamasaki H; Kuwaki K; Takedatsu H; Sata M
    Curr Pharm Des; 2009; 15(18):2110-9. PubMed ID: 19519448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of inflammatory bowel diseases: current concepts and future perspectives.
    Neurath MF
    Arch Immunol Ther Exp (Warsz); 2000; 48(2):81-4. PubMed ID: 10807047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapies for inflammatory bowel disease: from the bench to the bedside.
    Danese S
    Gut; 2012 Jun; 61(6):918-32. PubMed ID: 22115827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene transfer approaches for the treatment of inflammatory bowel disease.
    Wirtz S; Neurath MF
    Gene Ther; 2003 May; 10(10):854-60. PubMed ID: 12732871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of action.
    Mitsuyama K; Sata M
    Cytotherapy; 2009; 11(2):229-37. PubMed ID: 19241197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biologic therapy of inflammatory bowel disease].
    Baumgart DC; Wiedenmann B; Dignass AU
    Z Gastroenterol; 2003 Oct; 41(10):1017-32. PubMed ID: 14562200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocytapheresis in the treatment of patients with active ulcerative colitis.
    Bresci G
    Expert Rev Gastroenterol Hepatol; 2008 Oct; 2(5):639-43. PubMed ID: 19072341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Crohn disease, ulcerative colitis. When bacteria attack the intestinal wall....].
    Duchmann R; Lochs H; Kruis W
    MMW Fortschr Med; 1999 Dec; 141(51-52):48-51. PubMed ID: 10949626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paediatric inflammatory bowel disease in New Zealand.
    Yap J; Wesley A; Mouat S; Chin S
    N Z Med J; 2008 Oct; 121(1283):19-34. PubMed ID: 18841182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease.
    Sawada K
    Dis Colon Rectum; 2003 Oct; 46(10 Suppl):S66-77. PubMed ID: 14530661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prerequisites for therapy of inflammatory bowel diseases. Pathophysiology--symptomatology--diagnosis].
    Haag K; Schölmerich J
    Fortschr Med; 1991 Apr; 109(11):232-7. PubMed ID: 1855748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.